HER2-Low Breast Cancer with Brain Metastases
HER2-low breast cancer is a subtype of breast cancer characterized by low levels of the HER2 protein. When it spreads to the brain, it can cause serious complications, including neurological symptoms.
HER2-Low Breast Cancer: Trastuzumab-Deruxtecan Study
We are studying a new treatment for patients with HER2-low breast cancer and brain metastases to see if it helps shrink tumors and improve quality of life. This trial will also look at safety and how well patients tolerate the treatment.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have metastatic breast cancer with HER2-low status?
- Are you currently pregnant or breastfeeding?
- Have you had any major surgery in the last 3 weeks?
- Are you taking any corticosteroids like Prednisone or Dexamethasone regularly?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Ds-8201a
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
SCRI CCCIT Ges.m.b.H.
Med Dep Hematology, Med Oncology, Hemostaseology, Infectious Diseases & Rheumatology, oncologic cent
Salzburg, Austria
Medical University of Vienna
Department of Medicine I, Division of Oncology
Vienna, Austria
Vall D Hebron Institute Of Oncology
Medical Oncology
Alboraya, Spain
Sponsor: Medica Scientia Innovation Research S.L.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.